

# Gilles de la Tourette's syndrome

<https://marketpublishers.com/r/G091FF03782CEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G091FF03782CEN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Gilles de la Tourette's syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Gilles de la Tourette's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Gilles de la Tourette's syndrome Understanding

#### Gilles de la Tourette's syndrome: Overview

Tourette syndrome (TS) is a disorder that affects the body's brain and nervous system by causing tics — sudden, repetitive movements or sounds that some people make, seemingly without realizing it. A person with Tourette syndrome has multiple motor tics and at least one vocal tic. Tics are actually more common in teens than you might think. You may know someone who has either a motor tic (sudden, uncontrollable movements like exaggerated blinking of the eyes) or a vocal tic (sounds such as throat clearing, grunting, or humming). Tourette syndrome is a genetic disorder, which means it's the result of a change in genes that's either inherited (passed on from parent to child) or happens during development in the womb. As with other genetic disorders, someone may have a tendency to develop TS. But that doesn't mean the person will definitely get

it.

'Gilles de la Tourette's syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gilles de la Tourette's syndrome pipeline landscape is provided which includes the disease overview and Gilles de la Tourette's syndrome treatment guidelines. The assessment part of the report embraces, in depth Gilles de la Tourette's syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gilles de la Tourette's syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gilles de la Tourette's syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Gilles de la Tourette's syndrome.

## Gilles de la Tourette's syndrome Emerging Drugs Chapters

This segment of the Gilles de la Tourette's syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Gilles de la Tourette's syndrome Emerging Drugs

### Ecopipam: Emalex Biosciences

Ecopipam is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette Syndrome (TS) and for childhood onset fluency disorder (Stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Dopamine is a neurotransmitter in the central nervous

system, and its receptors have been classified into two “families” based on their genetic structure: “D1” (including subtypes D1 and D5) and “D2” (including subtypes D2, D3, and D4). D1-receptor super-sensitivity may be a mechanism for the repetitive and compulsive behaviors associated with Tourette Syndrome. The drug is currently in phase 2 of clinical trials for the treatment of Gilles de la Tourette's syndrome.

#### THX-110: Therapix Biosciences

THX-110 is a drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain. The drug is currently in phase 2 of clinical trials.

Further product details are provided in the report

#### Gilles de la Tourette's syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Gilles de la Tourette's syndrome drugs segregated based on following parameters that define the scope of the report, such as:

##### Major Players in Gilles de la Tourette's syndrome

There are approx. 4+ key companies which are developing the therapies for Gilles de la Tourette's syndrome. The companies which have their Gilles de la Tourette's syndrome drug candidates in the most advanced stage, i.e. phase II include, Emalex Biosciences.

##### Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

##### Late stage products (Phase III)

##### Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Gilles de la Tourette's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Gilles de la Tourette's syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gilles de la Tourette's syndrome therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gilles de la Tourette's syndrome drugs.

### Gilles de la Tourette's syndrome Report Insights

Gilles de la Tourette's syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Gilles de la Tourette's syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Gilles de la Tourette's syndrome drugs?

How many Gilles de la Tourette's syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gilles de la Tourette's syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gilles de la Tourette's syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Gilles de la Tourette's syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Emalex Biosciences

Therapix Biosciences

Catalyst Pharmaceuticals

KemPharm

Teva Pharmaceutical

Neurocrine Biosciences

Asarina Pharma

SOM Biotech

## Key Products

Ecopipam

THX-110

CPP 115

Gilles de la Tourette's syndrome prodrug therapeutic

Deutetrabenazine

NBI-98854

Sepranolone

SOM3355

## Contents

Introduction

Executive Summary

Gilles de la Tourette's syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Gilles de la Tourette's syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Gilles de la Tourette's syndrome companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Gilles de la Tourette's syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Deutetrabenazine: Teva Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Ecopipam: Emalex Biosciences

Product Description

Research and Development

Product Development Activities



Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Gilles de la Tourette's syndrome Key Companies

Gilles de la Tourette's syndrome Key Products

Gilles de la Tourette's syndrome- Unmet Needs

Gilles de la Tourette's syndrome- Market Drivers and Barriers

Gilles de la Tourette's syndrome- Future Perspectives and Conclusion

Gilles de la Tourette's syndrome Analyst Views

Gilles de la Tourette's syndrome Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Gilles de la Tourette's syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Gilles de la Tourette's syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Gilles de la Tourette's syndrome

Product link: <https://marketpublishers.com/r/G091FF03782CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G091FF03782CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970